The Evolution of Risk Assessment in Pulmonary Arterial Hypertension

Sandhya Murthy; Raymond Benza

doi:10.14797/LRPR7655

The Evolution of Risk Assessment in Pulmonary Arterial Hypertension

Methodist Debakey Cardiovasc J. 2021 Jul 1;17(2):134-144. doi: 10.14797/LRPR7655. eCollection 2021.

Authors

Sandhya Murthy¹, Raymond Benza²

Affiliations

¹ Montefiore Medical Center, Bronx, New York, USA.
² Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Abstract

Pulmonary arterial hypertension (PAH) is a chronic debilitating disease that carries an unacceptably high morbidity and mortality rate despite improved survival with modern therapies. The combination of several modifiable and nonmodifiable variables yields a robust risk assessment across various available clinical calculators. The role of risk calculation is integral to managing PAH and aids in the timely referral to expert centers and potentially lung transplantation. Studies are ongoing to determine the role of risk calculators in the framework of clinical trials and to elucidate novel markers of high risk in PAH.

Keywords: prognosis; pulmonary arterial hypertension; risk; survival.

MeSH terms

Familial Primary Pulmonary Hypertension
Humans
Hypertension, Pulmonary* / diagnosis
Hypertension, Pulmonary* / epidemiology
Hypertension, Pulmonary* / therapy
Lung Transplantation* / adverse effects
Pulmonary Arterial Hypertension*
Risk Assessment